Neuropathix, Inc.
OTC: NPTX0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- Other OTC
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Dean Petkanas
- Employees
- 6
- Headquarters
- Doylestown, United States
- IPO year
- 2019
- Market cap
- $28.1K
- Website
- https://neuropathix.com
Loading NPTX…
Loading profile data…Frequently asked questions about NPTX
What does Neuropathix, Inc. (NPTX) do?
Neuropathix, Inc. is a biopharmaceutical firm dedicated to identifying, advancing, and bringing to market innovative treatments derived from its exclusive platform of synthetic cannabinoid derivatives. The company's efforts are concentrated on the research and preclinical development of chemical compounds like KLS-13019, KLS-13023, and KLS-13022...
Where does NPTX trade?
Neuropathix, Inc. (NPTX) trades on the Other OTC.
What sector is NPTX in?
Neuropathix, Inc. (NPTX) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of Neuropathix, Inc.?
Dean Petkanas is the chief executive officer of Neuropathix, Inc. (NPTX).
Where is Neuropathix, Inc. headquartered?
Neuropathix, Inc. is headquartered in United States.
Does NPTX pay a dividend?
Neuropathix, Inc. (NPTX) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did NPTX go public?
Neuropathix, Inc. (NPTX) completed its initial public offering in 2019.